PathAI has introduced two innovative AI products, PathExplore™ Immuno-Oncology Profiling (IOP) and IHC Explore™, designed to aid cancer drug developers and clinical researchers by offering detailed AI-powered insights into the tumor microenvironment. These tools provide unprecedented single-cell and spatial resolution from routine pathology samples, facilitating biomarker discovery and a deeper understanding of treatment responses, crucial for developing next-generation cancer therapeutics.
The PathExplore IOP product quantifies tumor-infiltrating lymphocytes (TILs) and their spatial distribution using routine H&E samples, allowing researchers to assess immune phenotypes within the tumor core and periphery. This capability helps identify immune-inflamed, desert, or excluded characteristics, which are critical for determining tumor response to immunotherapy and improving patient survival outcomes. The product addresses the need for standardized and scalable methods to investigate immune infiltration patterns, which have previously been difficult to achieve.
IHC Explore™ offers spatial quantification of IHC biomarkers at single-cell resolution, overcoming the challenges of time-consuming, subjective, and low-resolution IHC scoring in early clinical settings. It provides a standardized panel of features to quantify IHC stain abundance, enabling precise identification of patients most responsive to treatment. PathAI’s partnership with Roche enhances the application of these AI insights into companion diagnostic development, streamlining the process. These advancements in AI-driven pathology tools promise significant improvements in cancer diagnosis and treatment, aligning with PathAI’s mission to advance precision medicine and improve patient outcomes.
Click here to read the original news story.